2014 News Releases

2015 | 2014 | 2013
DateTitle 
12/29/14Luminex Corporation To Present At J.P. Morgan Healthcare Conference
AUSTIN, Texas, Dec. 29, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 33rd Annual J.P. Morgan Healthcare Conference to be held January 12-15, 2015, in San Francisco, CA. The investor presentation will begin at 8:30 a.m. Pacific time (11:30 a.m. Eastern time) on Thursday, January 15, 2015.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. &nbs... 
Printer Friendly Version
10/27/14Luminex Corporation Reports Third Quarter 2014 Results
AUSTIN, Texas, Oct. 27, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the third quarter ended September 30, 2014. Financial and operating highlights include the following: Consolidated revenue of $56.7 million, a 12 percent increase over the third quarter of 2013. Assay revenue of $22.1 million, a 37 percent increase over the third quarter of 2013. Infectious disease assay sales comprised approximately 65 percent of total assay sales, w... 
Printer Friendly Version
10/15/14Luminex Corporation Announces Retirement of Patrick Balthrop, President and CEO
Nachum "Homi" Shamir to Become President and CEO Effective Immediately; Balthrop Will Continue as Consultant to the Board Through April 14, 2015 AUSTIN, Texas, Oct. 15, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Patrick J. Balthrop, Sr. has retired as President and CEO. The board of directors has named Nachum "Homi" Shamir as President and CEO. Mr. Balthrop has resigned as a director but will continue to serve the company and its shareholders as a consultant ... 
Printer Friendly Version
10/13/14Luminex Corporation Third Quarter Earnings Release Scheduled for October 27, 2014
AUSTIN, Texas, Oct. 13, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter of 2014 on Monday, October 27, 2014. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2014 on October 27, 2014, at 5:00 p.m. Eastern time. The conferen... 
Printer Friendly Version
09/29/14Luminex Receives FDA Clearance To Add New Clinical Targets And Additional Sample Type For Use With xTAG® Gastrointestinal Pathogen Panel
This comprehensive syndromic panel tests for greater than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in a single molecular test AUSTIN, Texas, Sept. 29, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA clearance to add three new targets to its xTAG® Gastrointestinal Pathogen Panel (GPP). The targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae. In addition, FDA has now cleared xTAG GPP fo... 
Printer Friendly Version
08/25/14Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
AUSTIN, Texas, Aug. 25, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the Morgan Stanley Global Healthcare Conference to be held September 8-10, 2014, in New York, NY. The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 9:10 a.m. Eastern time on Wednesday, September 10, 2014.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at... 
Printer Friendly Version
08/04/14Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
AUSTIN, Texas, Aug. 4, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Diagnostics Division is working on rapid diagnostics for the Ebola virus using Luminex xMAP® Technology. Luminex's MAGPIX® system was recently deployed to Africa to support research efforts to control the current outbreak.  The recent Ebola outbreak has so far claimed 729 lives across Guinea, Liberia, Nigeria, a... 
Printer Friendly Version
07/28/14Luminex Corporation Reports Second Quarter 2014 results
AUSTIN, Texas, July 28, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the second quarter ended June 30, 2014. Financial and operating highlights include the following: Consolidated second quarter revenues of $55.6 million, a 2 percent increase over the second quarter of 2013. Second quarter system sales of $8.3 million, a 9 percent increase over the second quarter of 2013.  Second quarter shipments of 268 multiplexing analyzers, ... 
Printer Friendly Version
07/07/14Luminex Corporation Second Quarter Earnings Release Scheduled for July 28, 2014
AUSTIN, Texas, July 7, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the second quarter of 2014 on Monday, July 28, 2014. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the second quarter ended June 30, 2014 on July 28, 2014, at 5:00 p.m. Eastern time. The conference call will be w... 
Printer Friendly Version
05/12/14Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for its New Sample-to-Answer System, ARIES™
AUSTIN, Texas, May 12, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex's growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile (C. diff). &nb... 
Printer Friendly Version
05/05/14Luminex Corporation Announces European Unveiling of its New Sample-to-Answer System at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
System's Innovative Design and Ease-of-Use Will Streamline Laboratory Workflow AUSTIN, Texas, May 5, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced it will unveil its new sample-to-answer system for infectious disease testing, ARIES™ at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). ARIES' scalable throughput, easy to use design, and networked data management software will deliver rapid results with a simple workflow. ... 
Printer Friendly Version
05/01/14Luminex Corporation To Present At UBS Global Healthcare Conference
AUSTIN, Texas, May 1, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the UBS Global Healthcare Conference to be held May 19-21, 2014, in New York, NY. The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 8:00 a.m. Eastern time on Monday, May 19, 2014.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. &nb... 
Printer Friendly Version
04/28/14Luminex Corporation Reports First Quarter 2014 Results
AUSTIN, Texas, April 28, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the first quarter ended March 31, 2014.  Financial and operating highlights include the following: Consolidated first quarter revenues reached $56.6 million, a 6 percent increase over the first quarter of 2013 Consolidated gross profit margin was 71 percent for the first quarter of 2014 First quarter assay revenue of $21.7 million, an 18 percent increase over the f... 
Printer Friendly Version
04/22/14Luminex Corporation Announces Norovirus as a Launch Menu Assay for its New Sample-to-Answer System, ARIES™
AUSTIN, Texas, April 22, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that norovirus will be the fourth assay in the launch menu for its new sample-to-answer system, ARIES™. The assay is designed to test for both GI and GII genogroups in a single, easy-to-use cassette. The previously announced items in the five assay launch menu targeted for the ARIES system also include: Flu A&B/RSV, HSV 1&2, and Clostridium difficile (C. diff). Future menu items will be ... 
Printer Friendly Version
04/07/14Luminex Corporation First Quarter Earnings Release Scheduled for April 28, 2014
AUSTIN, Texas, April 7, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the first quarter of 2014 on Monday, April 28, 2014. A press release announcing the results is scheduled for release after the close of trading. Management will hold a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2014 on April 28, 2014, at 5:00 p.m. Eastern time. The conference call will ... 
Printer Friendly Version
03/17/14Pioneering Human Protein Atlas Project Achieves a Major Milestone
Project Leverages Luminex's xMAP® Technology for Biobank Profiling Research AUSTIN, Texas, March 17, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that xMAP® Technology is playing a key role in the biobank profiling research within the Human Protein Atlas (HPA) project.  In the latest release of the protein atlas, the HPA announced coverage of over 80% of the human protein-coding genes and RNA expression data for more than 90% of the genes. http://phot... 
Printer Friendly Version
02/03/14Luminex Corporation Reports Fourth Quarter And Full Year 2013 Results
AUSTIN, Texas, Feb. 3, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) today announced financial results for the fourth quarter and year ended December 31, 2013.  Financial and operating highlights include the following: Consolidated fourth quarter revenue of $55.2 million, a 1 percent decline compared to the fourth quarter of 2012; full-year 2013 revenue was $213.4 million, a 5 percent increase over 2012 Fourth quarter royalty revenue of $9.3 million, a 23 percent increase over t... 
Printer Friendly Version
01/29/14Luminex Corporation To Present At 2014 Leerink Global Healthcare Conference
AUSTIN, Texas, Jan. 29, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 2014 Leerink Global Healthcare Conference to be held February 12 -13, 2014, in New York, NY. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 8:55 a.m. Eastern time on Thursday, February 13, 2014.  The presentation will be webcast live and may ... 
Printer Friendly Version
01/14/14Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
AUSTIN, Texas, Jan. 14, 2014 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that it expects to report results for the fourth quarter of 2013 on Monday, February 3, 2014. A press release announcing the results is scheduled for release after the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) Management will hold a conference call to discuss the operating highlights and financial results for the fourth quarter and twelve months ended Dece... 
Printer Friendly Version
01/02/14Luminex Corporation To Present At JP Morgan Healthcare Conference
AUSTIN, Texas, Jan. 2, 2014 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 32nd Annual JP Morgan Healthcare Conference to be held January 13-16, 2014, in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 4:30 p.m. Pacific time (7:30 p.m. Eastern time) on Wednesday, January 15, 2014.  The presentation ... 
Printer Friendly Version